Preparation method and use of respiratory syncytial virus antigen
Designing the RSV new F antigen dimer by removing specific epitope sequences to maintain the pre-F conformation in vitro, solving the problems of low yield and conformational stability of existing RSV vaccines, and achieving efficient stimulation of the production of neutralizing active antibodies and immune protection.
Patent Information
- Application Number
- PCT/CN2024/094846
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-12
- Filing Date
- 2024-05-23
- Publication Date
- 2024-11-21
AI Technical Summary
The existing RSV vaccines based on pre-F protein have problems with low yield and inability to maintain the pre-F conformation, which makes it difficult to stimulate the body to produce high school and active antibodies.
By removing post-F's unique I and IV epitopes and partial sequences of III epitopes shared by pre-F and post-F, a new F antigen dimer is designed to maintain it in the pre-F conformation in vitro and in vitro, thereby stimulating The body produces antibodies against pre-F epitope.
High yield (more than 30 mg/L) and effective stimulation of the production of high school and active antibodies, significantly improving the immune protection effect against RSV.
Smart Images

Figure CN2024094846_21112024_PF_FP_ABST
Abstract
Description
A method for preparing respiratory syncytial virus antigen and its application Technical Field
[0001] The present invention belongs to the field of biomedicine, and in particular relates to a protein for preventing respiratory syncytial virus infection and an application thereof. Background Art
[0002] Respiratory syncytial virus (RSV) is one of the most common pathogens causing lower respiratory tract infections in infants and young children worldwide. Nearly all children will be infected with RSV at least once before the age of two, leading to pneumonia or bronchitis, and even death. In immunocompromised and immunocompromised elderly individuals, RSV infection can cause severe lower respiratory tract symptoms and increase the risk of death. Therefore, the development of a safe, effective, and affordable vaccine to prevent RSV infection is a pressing global challenge.
[0003] RSV belongs to the Paramyxoviridae family and the genus Pneumovirus. Its genome is a single-stranded, negative-strand virus with a total length of 15.2 kilobases, encoding 11 viral proteins. RSV has two glycoproteins on its surface, G and F, which are important RSV antigens and the primary targets of neutralizing antibodies. The G protein shares only approximately 50% homology among different RSV subtypes; the F protein, on the other hand, is highly conserved, differing only approximately 10% between different RSV subtypes. Therefore, the F protein is the primary antigen for the design and development of a broad-spectrum RSV vaccine.
[0004] During the fusion process between the virus and the host cell membrane, the RSV F protein changes from the pre-F conformation with high potential energy and poor stability to the post-F conformation with low potential energy and relatively stable. The V and V epitopes are blocked, preventing the body from producing antibodies with high neutralizing activity. Therefore, the development of pre-F-based RSV vaccines has become a research hotspot for preventing RSV infection. Although there is currently no clinically available RSV vaccine, several pre-F protein-based vaccines have entered clinical trials worldwide. These vaccines are all based on the F protein monomer structure and modified [Krarup A., et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nature Communications, 2015, 6: 8143; Crank MC., et al. A proof of concept for structure-based vaccine design targeting RSV in humans. Science, 2019, 365, 505-509.] to enable it to maintain the pre-F conformation. However, according to literature reports, these protein vaccines all have problems such as low yield (less than 6 mg / L) [Joyce MG., et al. Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nature Structural & Molecμlar biology, 2016, 23(9): 811-820.] and inability to always maintain the pre-F conformation [Crank MC., et al. Science, 2019, 365, 505-509.].
[0005] Summary of the Invention
[0006] To address the challenges of the prior art, the inventors conducted research and developed a novel F antigen sequence modification. Specifically, the key design features of the present invention include: 1. Based on the RSV F protein sequence, a novel F antigen sequence is obtained by removing the post-F specific epitope I and IV sequences and the partial sequence of the epitope III shared by the pre-F and post-F groups; 2. Two novel F antigen sequences are concatenated together to form a novel F antigen dimer. These two design features maintain the novel F antigen dimer in the pre-F conformation both in vitro and in vivo, thereby stimulating the production of antibodies specific to the pre-F epitope and possessing high neutralizing activity.
[0007] The present invention provides a method for preparing a respiratory syncytial virus antigen, wherein the respiratory syncytial virus antigen is obtained by expressing the following antigen encoding gene:
[0008] A gene encoding a RSV F protein monomer from which the post-F-specific I and IV epitopes and the pre-F and post-F-shared III epitope have been removed, or two or more RSV F protein monomers concatenated together to obtain a respiratory syncytial virus antigen encoding gene;
[0009] Preferably, according to the F protein sequence of the RSVA2 strain (preferably the amino acid sequence shown in SEQ ID NO: 1), the N104-S146 segment (specifically as shown in SEQ ID NO: 2) and the V308-S552 segment (specifically as shown in SEQ ID NO: 3) are removed; S35 is mutated to T, and C37 is mutated to A; a linker sequence (for example, two amino acids of GS) is inserted between T103 and A147 to link them, thereby obtaining a gene of an RSV F protein monomer comprising the I and IV epitopes specific to post-F and the III epitope portion shared by pre-F and post-F; or two or more of the obtained new RSV F protein monomers are concatenated together to obtain a respiratory syncytial virus antigen encoding gene.
[0010] Preferably, the amino acid sequence from which the post-F-specific epitopes I and IV are removed is F387-D392 (FNPKYD) and K427-S436 (KNRGIIKTFS), and the amino acid sequence from which only the epitope III shared by pre-F and post-F is retained is V40-L45 (VSKGYL);
[0011] The amino acid sequence of the RSV F protein monomer from which the post-F-specific I and IV epitopes and the pre-F and post-F-shared III epitope portion have been removed is shown in SEQ ID NO: 4;
[0012] More preferably, the amino acid sequence of the respiratory syncytial virus antigen obtained by concatenating two monomers is as shown in SEQ ID NO: 5.
[0013] More preferably, a tag sequence and a nucleotide sequence encoding a stop codon are added to the 3' end.
[0014] Specifically, the encoding nucleotide sequence of the tag sequence is a nucleic acid sequence encoding 6 histidines, preferably, as shown in SEQ ID NO: 6.
[0015] Furthermore, the nucleotide sequence encoding the stop codon is a stop codon.
[0016] In a specific embodiment, the respiratory syncytial virus antigen encoding gene is expressed in a host cell via a recombinant expression vector to obtain the respiratory syncytial virus antigen; specifically, the starting vector of the recombinant vector is a mammalian cell expression vector such as a pCAGGS vector, and the host cell mammalian cell is such as a 293F cell; optionally, the step of collecting the cell supernatant after expression and purifying the respiratory syncytial virus antigen is also included.
[0017] The present invention provides a respiratory syncytial virus antigen obtained by the preparation method, preferably having an amino acid sequence as shown in SEQ ID NO: 5, or including a tag sequence as shown in SEQ ID NO: 6.
[0018] Further provided is a gene encoding the respiratory syncytial virus antigen.
[0019] The present invention also provides a recombinant expression vector and a recombinant host cell containing the encoding gene. Specifically, the starting vector of the recombinant vector is a mammalian cell expression vector such as a pCAGGS vector, and the host cell is a mammalian cell such as a 293F cell.
[0020] The present invention also provides an antigen composition comprising the respiratory syncytial virus antigen as an effective ingredient and an adjuvant, preferably the adjuvant is an aluminum adjuvant and an AddVax adjuvant.
[0021] The present invention also provides the use of the respiratory syncytial virus antigen in preparing a reagent for immunizing animals to obtain antibodies.
[0022] The dimeric antigen provided by the present invention not only maintains its pre-F conformation in vivo and in vitro, thereby stimulating the body to produce antibodies specific to the pre-F epitope and with high neutralizing activity, but also has the advantage of stimulating the body to produce more neutralizing antibodies. In addition, experiments have confirmed that the F antigen dimer of the present invention also has the advantage of high yield (exceeding 30 mg / L in experiments). BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1. Superdex 200Increase 10 / 300 (GE) molecular sieve chromatography and electrophoresis of RSV novel F antigen dimer.
[0024] Figure 2. Schematic diagram of immunization strategy.
[0025] Figure 3. RSV F-specific IgG antibody titers induced in cotton rats after immunization with RSV novel F antigen dimer.
[0026] Figure 4. In vivo conformational analysis of proteins after cotton rats were immunized with RSV novel F antigen dimers (ELISA was used to infer whether the antigen was pre-F or post-F in vivo).
[0027] Figure 5. The results of RSV A2 virus neutralizing antibody titers induced by cotton rats immunized with RSV novel F antigen dimers.
[0028] Figure 6 shows the results of RSVB9320 virus neutralizing antibody titers induced by cotton rats immunized with RSV novel F antigen dimers.
[0029] Figure 7. Live virus titers in various tissues of cotton rats immunized with RSV novel F antigen dimer and then challenged.
[0030] Figure 8. Pathological sections of lung tissue of cotton rats immunized with RSV novel F antigen dimer and then challenged. DETAILED DESCRIPTION
[0031] In order to make the purpose, technical solutions and advantages of the present invention more clear, the present invention is further described in detail below in conjunction with specific examples and with reference to the accompanying drawings, but it should not be understood as limiting the present invention. The experimental methods used in the examples are conventional methods well known to those skilled in the art unless otherwise specified. The materials, reagents, etc. used in the following examples can be obtained from commercial sources unless otherwise specified.
[0032] The sequence information is as follows:
[0033] SEQ ID NO: 1 (full-length sequence of RSV A2 strain F protein):
[0034] SEQ ID NO: 2 (amino acid sequence of the N104-V147 segment of the RSV A2 strain F protein):
[0035] SEQ ID NO: 3 (amino acid sequence of the V308-S552 segment of the RSV A2 strain F protein):
[0036] SEQ ID NO: 4 (amino acid sequence of the protein monomer of the present invention):
[0037] SEQ ID NO: 5 (amino acid sequence of the antigen of the present invention, excluding the tag sequence):
[0038] SEQ ID NO: 6 (amino acid sequence of the antigen of the present invention, including a histidine tag):
[0039] Example 1: Expression and purification of RSV novel F antigen dimer
[0040] According to the F protein sequence of the RSV A2 strain (as shown in the amino acid sequence of SEQ ID NO: 1), the N104-V147 segment (as shown in SEQ ID NO: 2) and the V308-S552 segment (as shown in SEQ ID NO: 3) were removed; a linker sequence (two amino acids of GS) was inserted between T103 and G148 to obtain the amino acid sequence of the RSV F protein monomer that does not contain the I and IV epitopes specific to post-F and the III epitope shared by pre-F and post-F (as shown in SEQ ID NO: 4). The amino acid sequences of the obtained new RSV F protein monomers were then concatenated in two (as shown in SEQ ID NO: 5), and a 6-histidine tag (as shown in SEQ ID NO: 6) was added to the 3' end. After codon optimization, the respiratory syncytial virus antigen encoding gene was obtained.
[0041] The obtained respiratory syncytial virus antigen encoding gene sequence was then cloned into the pCAGGS vector to obtain the pCAGGS-new F antigen dimer plasmid. The plasmid was then transfected into a 293F cell expression system for expression, and the cell supernatant was collected and purified after expression.
[0042] Chromatography was performed using Superdex 200 Increase 10 / 300 (GE) molecular sieves, and the elution peak around 13.5 ml (as shown in Figure 1) was collected for SDS-PAGE analysis. The protein in the elution volume around 13.5 ml had a size of approximately 55 kd under both non-reducing conditions (without DTT) and reducing conditions (with DTT), confirming that the protein obtained in this elution peak was a novel F antigen dimer.
[0043] Example 2: Affinity Analysis of Antibodies to RSV New F Antigen Dimers
[0044] The RSV novel F antigen dimer obtained in Example 1 was immobilized on an SM chip using the biomacromolecule interaction analysis system Biacore 8K. Then, a variety of antibody Fab fragments targeting different epitopes of the F protein were flowed on the chip surface to measure the affinity between the antigen and the various antibodies.In this embodiment, I epitope 4D7 [Flynn JA., et al. Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein. PLoS ONE, 2016, 11(10):e0164789.], II epitope Palivazumab [The IMPACT-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospi-talization from respiratory syncytial virus infection in high-risk infants. Pediatrics, 1998, 102, 531-537], III epitope MPE8 [Gilman MS.et al. Characterization of a prefusion-specific antibody that recognizes a quaternary, cleavage-dependent epitope on the RSV fusion glycoprotein. PLoS Pathogen, 2015, 11:e1005035.], IV epitope 101F [McLellan JS.et al. Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F. Journal of Virology, 2010, 84:12236-12244.], V epitope CR9501 [Gilman MS.et al. Transient opening of trimeric prefusion RSV F proteins. Nature Communications, 2019, 10:2105.] are selected. Epitope Am22 [McLellan JS. et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Scinece, 2013, 340(6136): 1113-1117.]. Biacore 8K analysis revealed the binding and affinity of RSV novel F antigen dimer to the antibody (as shown in Table 1). Blank cells indicate no binding between the antigen and the antibody.
[0045] Table 1 Binding of RSV novel F antigen dimer to antibodies and their affinity
[0046] Example 3: Experiment on Immunization of Cotton Rats with RSV New F Antigen Dimer
[0047] MF59 (AddaVax used below is an MF59-like adjuvant) and aluminum adjuvant are two commonly used adjuvants approved by the SFDA. The present invention selects these two adjuvants as vaccine adjuvants for animal experiments, which will have a direct guiding role in subsequent clinical trials; therefore, the present invention dilutes the antigen obtained in Example 1 with PBS solution to the required concentration, and then emulsifies it after mixing it with Alhydrogel aluminum adjuvant and AddVax adjuvant, and then immunizes female cotton rats aged 6-8 weeks in groups. The immunization grouping, the dose of immunogen used in each group, and the adjuvant situation are shown in Table 2, and the blank part indicates "none". The immunization strategy is shown in Figure 2. Each cotton rat received three vaccine immunizations on days 0, 21, and 42, respectively, by thigh muscle injection, with an inoculation volume of 200 μl each time, and 100 μl was inoculated in each thigh on both sides. Orbital blood was collected on days 19, 40, and 56, respectively. After the blood sample was allowed to stand, it was centrifuged at 3000 rpm for 10 minutes to obtain serum, which was inactivated in a 56°C water bath for 30 minutes and stored in a -80°C refrigerator for specific antibody titer detection and RSV neutralization experiments.
[0048] Table 2 Immunization groups, immunogen doses and adjuvants used in each group
[0049] Example 4: ELISA test to detect antigen-induced specific antibody titer
[0050] The RSV new F antigen dimer protein obtained in Example 1 was diluted to 3 μg / ml with ELISA coating solution and added to an ELISA 96-well plate (Coring, 3590), with 100 μl added to each well. After standing at 4°C for 12 hours, the coating solution was discarded, PBS was added to wash twice, and 5% skim milk powder prepared with PBS was used as a blocking solution. 100 μl was added to each well and blocked at 37°C for 1 hour. After blocking, the blocking solution was discarded and 100 μl of the serum gradient dilution sample obtained in Example 3 was added. The serum sample was diluted 4 times with the blocking solution starting from 50 times, for a total of 12 gradients; 100 μl of the blocking solution was directly added to the negative control well. After incubation at 37°C for 1 hour, the supernatant was discarded, the plate was washed 3 times with PBST, and the chicken anti-cotton rat IgG secondary antibody diluted 1:5000 in the blocking solution was added. After incubation at 37°C for 1 hour, the plate was washed 4 times with PBST. Add HRP-conjugated goat anti-chicken IgG tertiary antibody diluted 1:5000 in blocking solution, incubate at 37°C for 0.5 hours, and wash the plate 4 times with PBST. Add TMB colorimetric solution for color development, add 2M hydrochloric acid to terminate the reaction after an appropriate reaction time, and measure the OD on a microplate reader. 450 The antibody titer is defined as the highest serum dilution at which the reaction value is greater than 2.1 times the negative control value. When the reaction value at the lowest dilution (detection limit) is still less than 2.1 times the negative control value, the titer of the sample is defined as half of the lowest dilution, i.e. 1:25.
[0051] The results, as shown in Figure 3, show that throughout the immunization process, specific antibody levels in the serum of cotton rats in each immunization group increased significantly with the number of immunizations. The highest antibody levels were achieved after three immunizations at doses of 10 μg aluminum adjuvant and 10 μg AddaVax adjuvant. This result demonstrates that the RSV novel F antigen dimer effectively activates the antibody response in cotton rats.
[0052] Example 5: ELISA assay to detect the conformation of F neoantigen dimers in vivo
[0053] The RSV novel F antigen dimer protein and RSV post-F protein obtained in Example 1 were diluted to 3 μg / ml with ELISA coating buffer and added to a 96-well ELISA plate (Coring, 3590), with 100 μl added to each well. After incubation at 4°C for 12 hours, the coating buffer was discarded, and the plates were washed twice with PBS. Then, 100 μl of 5% skim milk powder in PBS was added to each well as a blocking buffer and blocked at 37°C for 1 hour.
[0054] The serum samples collected after the three immunizations obtained in Example 3 were diluted 4 times with blocking solution starting from 25 times, and after a total of 12 gradient dilutions, they were mixed with an equal volume of 6μg / ml RSVpost-F protein solution prepared with blocking solution and incubated at 37°C for 1 hour. Then, they were incubated with a 96-well plate coated with RSV new F antigen dimer protein at 7°C for 1 hour. After discarding the supernatant, the plate was washed 3 times with PBST, and the secondary antibody of chicken anti-cotton rat IgG diluted 1:5000 with blocking solution was added. After incubation at 37°C for 1 hour, the plate was washed 4 times with PBST. After adding the tertiary antibody of sheep anti-chicken IgG coupled to HRP diluted 1:5000 with blocking solution, the plate was incubated at 37°C for 0.5 hours, and the plate was washed 4 times with PBST. TMB colorimetric solution was added for color development, and 2M hydrochloric acid was added to terminate the reaction after an appropriate reaction time. The OD was detected on an enzyme reader. 450 Read the value.
[0055] The serum samples collected after the three immunizations obtained in Example 3 were diluted 4 times with blocking solution from 50 times, and after a total of 12 dilutions, they were directly incubated at 37°C with a 96-well plate coated with RSVpost-F protein that had been washed with PBS. After 1 hour, the supernatant was discarded, the plate was washed 3 times with PBST, and the secondary antibody of chicken anti-cotton rat IgG diluted 1:5000 with blocking solution was added. After incubation at 37°C for 1 hour, the plate was washed 4 times with PBST. After adding the tertiary antibody of sheep anti-chicken IgG coupled to HRP diluted 1:5000 with blocking solution, the plate was incubated at 37°C for 0.5 hours, and the plate was washed 4 times with PBST. TMB colorimetric solution was added for color development, 2M hydrochloric acid was added after the appropriate reaction time to terminate the reaction, and the OD was detected on the enzyme reader. 450 Read the value.
[0056] The antibody titer calculation method is the same as in Example 3. The data of the specific binding antibodies (three exemptions) in the three-free serum in Example 3, the data of the direct binding of serum and post-F (direct), and the data of the binding of serum and post-F to RSV F protein (competition) after competition are jointly analyzed (as shown in Figure 4). The three-free data are significantly different from the direct data, but there is no statistical difference with the competition data. This result shows that the RSV new F antigen dimer protein exists essentially in the form of pre-F in vivo. Although the directly bound data show that there is a certain proportion of antibodies that can bind to post-F in serum, it is because pre-F and post-F share an epitope, such as the known II and IV epitopes, and there may also be some unknown common binding antibodies.
[0057] Example 6: Virus Neutralization Experiment with Immune Serum
[0058] The serum obtained in Example 3 was diluted initially at 1:5, and then diluted 4-fold in 7 gradients, and then mixed with an equal volume of 200 TCID 50RSVA2 and RSVB9320 were mixed. After incubation at 37°C for 1 hour, 100 μl of the mixture was added to a 96-well plate with a HEp-2 cell confluence of approximately 70%. After incubation at 37°C for 2 hours, the mixture was discarded and 100 μl of 2% FBS DMEM medium was added. After incubation at 37°C for 4 days, the medium was discarded, the cells were washed twice with PBS, and ice-cold 80% acetone solution was added to fix them for 20 minutes. The supernatant was discarded, and after washing twice with PBS, 100 μl of 5% skim milk powder prepared with PBS was added to each well as a blocking solution, and the cells were blocked at 37°C for 1 hour. After blocking, the blocking solution was discarded, and 100 μl / well of a 3 μg / ml Palivazumab primary antibody solution prepared with the blocking solution was added. After incubation at 37°C for 1 hour, the plate was washed 3 times with PBST. Add HRP-conjugated goat anti-human IgG secondary antibody diluted 1:5000 in blocking solution, incubate at 37°C for 1 hour, and wash the plate 4 times with PBST. Add TMB colorimetric solution for color development, add 2M hydrochloric acid to terminate the reaction after an appropriate reaction time, and measure the OD on a microplate reader. 450 The antibody titer is defined as the highest serum dilution at which the reaction value is greater than 2.1 times the negative control value. When the reaction value at the lowest dilution (detection limit) is still less than 2.1 times the negative control value, the titer of the sample is defined as half of the lowest dilution, i.e. 1:25.
[0059] The results, as shown in Figures 5 and 6, show that throughout the immunization process, neutralizing antibody levels in the serum of cotton rats in each immunization group increased significantly with the number of immunizations. The highest antibody levels were achieved after three immunizations at the 10 μg aluminum adjuvant dose and the 3 μg AddaVax adjuvant dose. This result demonstrates that the RSV novel F antigen dimer effectively stimulates the production of neutralizing antibodies in cotton rats, achieving immune protection.
[0060] Example 7: Cotton rat challenge protection experiment
[0061] The cotton rats in Example 3 were infected with 10 5 TCID 50 RSVA2 virus (as shown in Figure 2) was killed 5 days later, and the lungs, trachea and nasal cheek bones were removed and the tissues were homogenized for virus titer (TCID 50 The results are shown in Figure 7. Compared with the PBS control group, the viral load in various tissues of cotton rats in the vaccine group was significantly reduced, showing a good protective effect.
[0062] Example 8: Protective Effect of Vaccine on Cotton Rat Tissues
[0063] The lung and trachea samples in Example 7 were immersed in 4% paraformaldehyde solution for fixation. After the lung tissue samples were sliced, hematoxylin-eosin staining was used to observe the lung lesions. The results are shown in Figure 8. The lungs of the cotton rats in the PBS group had inflammatory cell infiltration, alveolitis and other injuries. In the immunized group of cotton rats, whether using aluminum adjuvant or AddaVax adjuvant, the lung damage caused by the virus attack was greatly alleviated, showing mild damage, the alveoli were clearly visible, and there were only a few inflammatory cell infiltrations; these mild lung injuries were mainly caused by a large one-time attack dose. The above results show that the RSV new F antigen dimer as a vaccine can greatly alleviate the lung damage caused by RSV A2 virus infection.
Claims
1. A method for preparing a respiratory syncytial virus antigen, characterized in that: The respiratory syncytial virus antigen is expressed by the following antigen encoding gene: A gene of a RSV F protein monomer from which epitopes I and IV specific to post-F and epitope III common to pre-F and post-F are removed, or two or more thereof are connected in series to obtain a respiratory syncytial virus antigen encoding gene; Preferably, according to the F protein sequence of the RSV A2 strain (preferably the amino acid sequence shown in SEQ ID NO: 1), the N104-S146 segment (specifically as shown in SEQ ID NO: 2) and the V308-S552 segment (specifically as shown in SEQ ID NO: 3) are removed; S35 is mutated to T, and C37 is mutated to A; a linker sequence (for example, two amino acids GS) is inserted between T103 and A147 to link them, so as to obtain a gene of an RSV F protein monomer comprising the I and IV epitopes specific to post-F and the III epitope portion shared by pre-F and post-F; or two or more of the obtained new RSV F protein monomers are connected in series to obtain a respiratory syncytial virus antigen encoding gene.
2. The preparation method according to claim 1, characterized in that The amino acid sequences with the I and IV epitopes specific to post-F removed were F387-D392 (FNPKYD) and K427-S436 (KNRGIIKTFS), and the amino acid sequence retaining only the III epitope portion common to pre-F and post-F was V40-L45 (VSKGYL); The amino acid sequence of the RSV F protein monomer from which the post-F-specific I and IV epitopes and the pre-F and post-F-shared III epitope portion are removed is shown in SEQ ID NO: 4; Preferably, the amino acid sequence of the respiratory syncytial virus antigen obtained by connecting two monomers in series is as shown in SEQ ID NO:
5.
3. The preparation method according to claim 1, characterized in that: A tag sequence and a nucleotide sequence encoding a stop codon are also added at the 3' end.
4. The preparation method according to claim 3, characterized in that: The encoding nucleotide sequence of the tag sequence is a nucleic acid sequence encoding 6 histidines, preferably, as shown in SEQ ID NO:
6. Furthermore, the nucleotide sequence encoding the stop codon is a stop codon.
5. The preparation method according to any one of claims 1 to 3, characterized in that: The respiratory syncytial virus antigen encoding gene is expressed in a host cell via a recombinant expression vector to obtain the respiratory syncytial virus antigen; specifically, the starting vector of the recombinant vector is a mammalian cell expression vector such as a pCAGGS vector, and the host cell mammalian cell is such as a 293F cell; optionally, it also includes the steps of collecting the cell supernatant after expression and purifying the respiratory syncytial virus antigen.
6. The respiratory syncytial virus antigen obtained by the preparation method according to any one of claims 1 to 5, preferably having an amino acid sequence as shown in SEQ ID NO: 5, or as shown in SEQ ID NO: 6 after including a tag sequence.
7. The gene encoding the respiratory syncytial virus antigen as claimed in claim 6.
8. A recombinant expression vector and a recombinant host cell containing the coding gene according to claim 7, specifically, the starting vector of the recombinant vector is a mammalian cell expression vector such as a pCAGGS vector, and the host cell is a mammalian cell such as a 293F cell.
9. An antigen composition comprising the respiratory syncytial virus antigen as claimed in claim 6 as an effective ingredient and an adjuvant, wherein the adjuvant is preferably an aluminum adjuvant and AddVax adjuvant.
10. Use of the respiratory syncytial virus antigen according to claim 6 in preparing a reagent for immunizing an animal to obtain antibodies.
Citation Information
Patent Citations
Substitutions-modified prefusion RSV f proteins and their use
CN109069611A
Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (RSV) infections
CN111344008A
Conformationally stabilized RSV pre-fusion f proteins
CN111405907A
RAAV vector vaccine for preventing respiratory syncytial virus
CN114685627A
RSV recombinant antigen as well as preparation method and application thereof
CN115772230A
